title: Treatment of relapsing-remittent multiple sclerosis with recombinant human interferon-alfa-2a: design of a randomised, placebo-controlled, double blind trial in Norway.
abstract: A multicentre, randomised, double-blind, placebo controlled study to evaluate the efficacy and safety of 4.5 and 9.0 MIU recombinant human interferon alfa-2a (Roferon-A) given thrice weekly in patients with relapsing-remittent multiple sclerosis is described. The patients are treated for 6 months followed by a 6 months drug-free period. The primary objective is to determine new disease activity analysed by monthly MRI with gadodiamide (GdDTPA-BMA, Omniscan). The study is conducted at eight centers in Norway and is completed in January 1996.
authors.affiliation: Department of Neurology, University of Bergen, Norway.
authors.forename: H
authors.initials: H
authors.lastname: Nyland
authors.forename: K M
authors.initials: KM
authors.lastname: Myhr
authors.forename: F
authors.initials: F
authors.lastname: Lillås
authors.forename: A I
authors.initials: AI
authors.lastname: Smievoll
authors.forename: T
authors.initials: T
authors.lastname: Riise
authors.forename: M
authors.initials: M
authors.lastname: Nortvedt
authors.forename: R
authors.initials: R
authors.lastname: Nilsen
mesh_terms: D003287:Contrast Media; D004311:Double-Blind Method; D019786:Gadolinium DTPA; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy*; D009664:Norway; D011994:Recombinant Proteins; D012008:Recurrence; D012074:Remission Induction / Q000379:methods
chemical_list: D003287:Contrast Media; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; C064925:gadodiamide; D019786:Gadolinium DTPA